Jefferies upgrades Dr. Reddy’s stock rating on margin outlook
Jefferies upgraded Dr. Reddy’s Laboratories (RDY) from Underperform to Hold, raising its price target to INR1,320.00. The firm cited a 15% Ebitda beat in Q3, strong margins, and improved earnings estimates. Dr. Reddy’s reported $905M in revenue, slightly above forecasts, with improved margins. The company expects to resume Semaglutide supplies and U.S. approval for bAbatacept in late 2026.
How this was made
The 30-second read
Why it matters
The analyst's revised earnings estimates and price target provide a new data point for traders.
Market read
Analyst upgrade with higher target may trigger buying interest in RDY.
What to watch
Potential regulatory risks for upcoming drug approvals could temper upside.
Background
Jefferies' research note highlights Dr. Reddy's recent earnings beat and margin recovery.
Ticker impact
Jefferies upgraded Dr. Reddy's Laboratories (RDY) to Hold and raised its price target to INR1,320, citing a 15% EBITDA beat and higher margin outlook.
likely upward pressure as the market prices in the margin-driven earnings outlook.
Analyst upgrade with a new target is a fresh catalyst that can move the stock in the short term.
Market effects
Improved margin outlook may lift other Indian pharma peers.
Positive for the Indian healthcare sector.
Limited to investors tracking emerging market pharma.
Counterpoint
The upgrade to Hold may be modest; investors could wait for further guidance before buying.
Key entities
- Analyst FirmJefferies
Provided the upgrade and target revision.
- CompanyDr. Reddy's Laboratories
Subject of the upgrade and earnings beat.
